11 research outputs found

    Actual vs Expected Reductions in Systolic Blood Pressure and LDL-cholesterol in Trials of ‘Polypills’.

    No full text
    *<p>rounded to nearest 10 mm Hg;</p>**<p>based on mean baseline SBP &amp; standard dose equivalence (from Law 2009) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052145#pone.0052145-Law1" target="_blank">[4]</a>;</p>∧<p>mean baseline LDL × percentage reduction in LDL cholesterol for the statin at that dose (from Law 2003) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052145#pone.0052145-Law2" target="_blank">[5]</a></p>#<p>estimate: two drugs at half dose therefore an overestimate of likely effect;</p>##<p>estimate: two drugs at half dose therefore an underestimate of likely effect; 12.7 mmHg for two drugs at standard dose;</p>β<p>estimate: three drugs at standard dose; 15.2 mmHg for three drugs at half standard dose.</p

    Baseline Characteristics and Study Quality of included Randomised Controlled Trials.

    No full text
    *<p>BP not assessed in meta-analysis as both arms contained an anti-hypertensive;</p>**<p>Following placebo 12 weeks of cross-over RCT;</p>#<p>Double-blind 9-arm with varying medication components and number of components. Only three arms were used in this meta-analysis: the polycap, aspirin and simvastatin arms;</p><p>BP = blood pressure and measured in mmHg; SBP = systolic blood pressure; DBP = Diastolic blood pressure; Total chol. = total cholesterol in mmol/L; LDL = LDL cholesterol in mmol/L; AE = adverse events; TLC = therapeutic lifestyle changes; SD = standard deviation; CVD = cardiovascular disease.</p
    corecore